• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Rifaximin

Modulation of Gut Microbiota by Rifaximin in PD Patients

May 22, 2019

https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Modulation of Gut Microbiota by Rifaximin in PD Patients

DESCRIPTION:
Conditions:   Parkinson Disease;   Inflammation
Intervention:   Drug: Rifaximin 550 MG
Sponsor:   Taipei Medical University Shuang Ho Hospital
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03958708

FIRST POSTED:
Wed, 22 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/22/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

Powered by Urgent Research

Copyright © 2025 Urgent Research